Background
==========

Primary aldosteronism is defined as the autonomic aldosterone secretion from the glomerulosa zone of adrenal cortex, making an inappropriately high level of the hormone regardless of reninangiotensin system and physiological requirements \[[@b1-amjcaserep-18-963]\]. Primary aldosteronism is usually caused by the presence of aldosterone-producing adrenocortical adenoma (Conn's adenoma) or adrenal hyperplasia \[[@b2-amjcaserep-18-963]\]. Health consequences of this adrenal syndrome are partly mediated by long-standing hypertension and refractory hypokalemia \[[@b2-amjcaserep-18-963],[@b3-amjcaserep-18-963]\]. The other issue is related to the cardiac effects of aldosterone related to its receptor expression, i.e. mineralocorticoid receptor (MR), in cardiomyocytes and cardiac fibroblasts \[[@b4-amjcaserep-18-963]\]. Their potential exposure to high circulating aldosterone leads to cardiac hypertrophy, myocardial fibrosis and endothelial dysfunction that is unrelated to blood pressure elevation. These emphasizes the concept that excess activation of MR, rather than aldosteronism itself, is the key to increasing adverse outcomes whenever aldosterone secretion is overtly enhanced \[[@b5-amjcaserep-18-963]\].

Cardiac involvement in primary aldosteronism is well documented, mostly in the form of left ventricular (LV) hypertrophy and diastolic dysfunction \[[@b6-amjcaserep-18-963]\] while right ventricular (RV) abnormalities has not been revealed \[[@b7-amjcaserep-18-963]\]. Herein we describe the case of a patient with primary aldosteronsim due to Conn's adenoma who presented with biventricular cardiac hypertrophy, which reverses upon aldosterone normalization following adrenalectomy. The fact that the patient also exhibited ostium secundum-type atrial septal defect (ASD) made this case unique and provided interesting information regarding pathophysiologic role of aldosterone in cardiac sequelae, including its effect on the RV. We present this case to highlight the salient point of the biventricular manifestation of cardiac changes in patient with primary aldosteronism.

Case Report
===========

Presentation, history, and physical examination on hospital admission
---------------------------------------------------------------------

In March 2014, a 33-year-old Javanese woman presented with dyspnea and palpitations at rest and during the night. The patient denied any recent weight gain, peripheral edema, headache, chest pain, fever, or any other constitutional symptoms. She had suffered from hypertension since the age of 20 years, which had been treated intermittently.

On physical examination, she had dyspnea at rest, was alert, but anxious, and her blood pressure was 170/115 mmHg, with a heart rate of 112 beats per minute, and labored respiration at 32 breaths per minute. During her latest hospitalization, peaks of systolic blood pressure were noted of up to 210 mmHg, with elevated jugular venous pressure. Cardiac examination showed both LV and RV enlargement. Cardiac auscultation detected a fixed split S2 with a loud component and a grade 3/6 ejection systolic murmur which was audible at the upper left sternal border and a diastolic gallop that could be heard at the cardiac apex. The patient had bilateral fine crepitation in the lower zones of the lungs. Abdominal examination showed no organomegaly, no palpable mass, and no abdominal bruits. Neurological examination of the lower limbs showed muscular weakness in both legs with a reduced motor power of 3--4/5. The lower limbs showed symmetric palpable pulses, no pedal edema, and no muscular atrophy.

Past medical history and previous investigations
------------------------------------------------

In 2002, she had been diagnosed by echocardiography as having an ostium secundum ASD. Hypokalemia was first documented at a regional hospital in 2007 when she suffered from pre-eclampsia during pregnancy. She had been treated with potassium supplements and several antihypertension medications. However, neither satisfactory blood pressure control nor normal serum potassium levels were achieved during follow-up, and the patient began to complain of increasing weakness. The patient reported that among members of her family, only her mother had suffered from hypertension.

In 2008, the patient had initially sought a specialist endocrine consultation at our hospital when her hypokalemia resulted in disabling generalized muscle weakness and intense muscle cramps. On her admission in 2008, the following studies were performed, which confirmed a diagnosis of primary aldosteronism. The supine morning plasma aldosterone concentration (PAC) and plasma renin activity (PRA) were 56 ng/mL (N≤15 ng/mL) and 0.13 ng/mL/hour (N=0.5--3.3 ng/mL/hour), respectively. The PAC to PRA ratio was calculated as 430.7 ng/dL per ng/mL/hour (N≤30 ng/dL per ng/mL/hour) ([Table 1](#t1-amjcaserep-18-963){ref-type="table"}). Ultrasound of the abdomen showed a mass (3.4×2.3×2.1 cm) in the right suprarenal area that was confirmed with computed tomography (CT) to be an adrenal tumor. The patient had been referred for adrenalectomy, but she initially declined surgery and preferred to remain on medication. She was discharged home with a blood pressure of 145/90 mmHg and a serum potassium level of 3.2 mmol/L with the medications that included spironolactone, captopril, amlodipine, bisoprolol, and potassium chloride tablets. The patient became lost to follow-up for six years, until March 2014. During the period between 2008 to 2014, she was admitted twice to two separate hospitals for episodes of heart failure.

Investigations on current hospital admission
--------------------------------------------

On admission of the patient to our hospital in March 2014, preliminary laboratory investigations showed severe hypokalemia (2.2 mmol/L) which was refractory (range, 1.9--2.6 mmol/L) even with repeated potassium supplementation. Urinary potassium excretion was 43 mmol/24 h indicating a renal loss of potassium. The serum magnesium level was normal, while the sodium concentrations were in the high normal limit (143 mmol/L). Serum creatine phosphokinase (CPK) was elevated at 1,257 IU/L, and creatine kinase isoenzyme myocardial band (CKMB) was 221 IU/L. Arterial blood gas analysis showed metabolic alkalosis and ventilation-perfusion mismatch secondary to pulmonary edema. Renal function tests showed normal serum urea and creatinine. Urinalysis showed no proteinuria or myoglobinuria.

Chest X-ray showed cardiomegaly, with a cardiothoracic ratio of 74.3% ([Figure 1](#f1-amjcaserep-18-963){ref-type="fig"}), and right atrial (RA) and RV enlargement with pulmonary edema. The electrocardiogram (ECG) showed sinus tachycardia with a ventricular rate of 112 beats per minute, left axis deviation, LV hypertrophy with strain, and alteration in ventricular repolarization consistent with hypokalemia with nonspecific ST-T segment depression, and flattened T wave with a prominent U wave. Serum potassium level was 2.1 mmol/L.

Based on initial findings, a diagnosis of acutely decompensated heart failure (ADHF) with hypokalemic myopathy was made, and the patient was immediately treated with oxygen therapy, intravenous isosorbide dinitrate, furosemide, and potassium replacement. Then, a conventional heart failure regimen was begun that included a non-selective β-receptor antagonist and α1-receptor antagonist (carvedilol), an angiotensin converting enzyme (ACE) inhibitor (ramipril), a dihydropyridine calcium antagonist (amlodipine), and an aldosterone receptor antagonist (spironolactone). A serum potassium level was maintained of at least \>3 mmol/L with parenteral potassium infusion and tablets.

Transthoracic echocardiography was performed and showed concentric hypertrophy of the LV, with an interventricular septal (IVS) thickness of 14 mm (N=6--9 mm); LV posterior wall thickness in end diastole of 17 mm (N=6--11 mm); LV mass of 473.6 g (N=66--150 g); LV mass index of 284.4 g/m2 (N=43--95 g/m^2^)); and RV wall thickness of 8 mm in diastole (N≤5 mm). There was four-chamber cardiac dilatation, global ventricular hypokinetic and LV systolic dysfunction, with an ejection fraction of 17% (Teichholz method). A large interatrial septum gap was present with a defect size of 2.4×2.7 cm, with a left-to-right shunt confirming the diagnosis of ostium secundum ASD. The RA and the RV were dilated, and the right ventricular systolic pressure (RVSP) of 60 mmHg indicated moderately severe pulmonary arterial hypertension (PAH). The echocardiography results are shown in [Figure 2](#f2-amjcaserep-18-963){ref-type="fig"}.

An abdominal CT scan ([Figure 3A, 3B](#f3-amjcaserep-18-963){ref-type="fig"}) was performed and compared with the previous scans, and showed an enlarged adrenal mass, from 3.4 cm in diameter in 2008 to approximately 4 cm in diameter in 2014. The tumor was minimally enhanced after contrast injection with low attenuation (+5 Hounsfield units). The absolute washout was calculated as 68%, and the mass was considered as a lipid-poor adenoma.

The investigations of endocrine function showed that her PAC failed to be suppressed after 120 minutes of captopril 50 mg, and the PAC-to-PRA ratio was still elevated further, which confirmed the diagnosis of primary aldosteronism \[[@b8-amjcaserep-18-963]\]. Other adrenal hormone levels were within normal limits. The diagnoses made at this time were of a right adrenal adenoma and biochemical diagnosis of primary aldosteronism, with acute heart failure, decreased LV systolic dysfunction, hypertensive heart disease, severe hypokalemia, rhabdomyolysis, left-to-right cardiac shunt due to a secundum ASD with moderate pulmonary hypertension (WHO functional class II). On this hospital admission, adrenalectomy was performed as the patient was willing to undergo surgery, and the blood pressure was adequately controlled before surgery.

Surgical management on current hospital admission
-------------------------------------------------

After sufficient pre-operative preparation, the patient underwent open adrenalectomy and exploration of the right adrenal mass via a posterior approach. The resected adrenal gland was a single, well defined and encapsulated yellowish nodule which weighed 27.9 g and measured 4.1×2.6×1.5 cm ([Figure 3C, 3D](#f3-amjcaserep-18-963){ref-type="fig"}). Histopathology examination confirmed a diagnosis of a benign adrenocortical adenoma ([Figure 4](#f4-amjcaserep-18-963){ref-type="fig"}).

Patient follow-up and outpatient management
-------------------------------------------

The patient made an uncomplicated recovery post-operatively. Immediately after the removal of the tumor, the PAC was found to be reduced to 8 ng/mL, and the PAC-to-PRA ratio dropped to nearly normal levels. Her serum potassium concentration was normalized without any supplementation. Approximately three days after surgery, the patient remained clinically stable and had adequate blood pressure control with ramipril 5 mg qd. Her postoperative biochemistry showed a serum potassium of 4.1 mmol/L and normal CPK and CKMB. The patient was discharged home and showed stable biochemical findings on follow-up outpatient visits.

Repeated echocardiography in September 2015 demonstrated improvement in the LV and RV size. Her LVEF had improved from 17% at presentation to 56% at 18 months after adrenalectomy ([Table 2](#t2-amjcaserep-18-963){ref-type="table"}). Right cardiac catheterization showed a mean right atrial pressure (RAP) of 10 mm Hg, a pulmonary artery pressure (PAP) of 54/29 mmHg (mean 42 mmHg), pulmonary vascular resistance (PVR) of 597 dyn s/cm^5^, and a mean pulmonary capillary wedge pressure of 11 mmHg. The pulmonary artery blood flow (Qp) relative to systemic blood flow (Qs) was 3.8 (Qp/Qs \>1.5). Given the significant ASD, particularly with a high PAP and PVR, she was referred for an open surgical closure of her ASD. However, she refused to undergo cardiac surgery because of financial constraints. At her last visit to the clinic in December 2015, the patient was still on ramipril 5 mg qd and remained symptom-free with a blood pressure of 130/80 mmHg and normal potassium level. Currently, her degree of heart failure is stable. At the time of writing this case report, surgical closure of the ASD remains to be undertaken.

Discussion
==========

This case report is of a 33-year-old woman with an adrenocortical adenoma and a history of primary aldosteronism and repeated hospital admissions with heart failure. Primary aldosteronism is a known cause of secondary hypertension with it sequelae \[[@b2-amjcaserep-18-963],[@b5-amjcaserep-18-963]\]. The mineralocorticoid, aldosterone, is a hormone that when in excess can have adverse effects on the cardiovascular system \[[@b5-amjcaserep-18-963]\]. Studies have shown that the effects on the heart include increased intercellular matrix and microvascular remodeling, as well as atrial and ventricular fibrosis \[[@b6-amjcaserep-18-963],[@b9-amjcaserep-18-963],[@b10-amjcaserep-18-963]\].

In this case report, the echocardiography showed not only changes in the LV, but also biventricular cardiac hypertrophy, four chamber dilatation, and global hypokinetic cardiac function, resembling hypertrophic cardiomyopathy \[[@b11-amjcaserep-18-963]\]. The patient in this case study was also diagnosed with an ostium secundum type ASD, which is a common form of congenital heart disease diagnosed in adults \[[@b12-amjcaserep-18-963]\]. As an isolated lesion, ASD causes a left-to-right cardiac shunt and volume overload in the right heart chamber, leading to remodeling of the RV \[[@b13-amjcaserep-18-963]\]. Pulmonary arterial hypertension, in this case, could have resulted in a pressure overload state to the RV, leading to concentric hypertrophy but the right ventricular venous pressure estimated by echocardiography was not high enough (60 mm Hg) to induce right-heart failure. In this case, the pre-existing ASD may have served to mitigate pulmonary congestion via a left-to-right shunt.

To our knowledge, there have been only three previously published cases in the literature of patients with primary aldosteronism and heart failure \[[@b14-amjcaserep-18-963]--[@b16-amjcaserep-18-963]\]. There have been no previous case reports of primary aldosteronism and heart failure accompanied by biventricular hypertrophy, and congenital heart disease, such as ASD. Of the previously reported cases, laparoscopic adrenalectomy was performed in two cases for unilateral adrenocortical adenoma, while the other case was treated pharmacologically \[[@b14-amjcaserep-18-963]--[@b16-amjcaserep-18-963]\]. These previously reported cases showed an improvement in cardiac function and following treatment, either with surgery or with the use of a miner-alocorticoid antagonist \[[@b14-amjcaserep-18-963]--[@b16-amjcaserep-18-963]\]. Sugishita et al. reported RV failure as the predominant feature associated with gross RV hypertrophy, and as the patient had significant LV involvement as well, they used the term 'cardiomyopathy' in their case \[[@b14-amjcaserep-18-963]\]. A possible explanation for RV hypertrophy in primary aldosteronism is that the RV is the first cardiac chamber on which aldosterone can produce its effects. Experimental studies by Weber and Brilla in a rat model support our finding that aldosteronism can be associated with cardiac remodeling in both the LV and RV \[[@b17-amjcaserep-18-963]\].

A follow-up echocardiography following adrenalectomy of this case report was performed at 18 months after complete biochemical remission from primary aldosteronism. The LV mass index was reduced by 142.4 g/m^2^ by 18 months, consistent with the changes in the LV and RV structure, mid-wall fractional shortening (FS), E/A ratio and E-wave deceleration time also improved at ([Table 2](#t2-amjcaserep-18-963){ref-type="table"}). In the 4E-Left Ventricular Hypertrophy Study, LV mass reduction of 27 g/m^2^ was demonstrated at nine months in patients taking eplerenone and enalapril \[[@b18-amjcaserep-18-963]\] through blockade of the renin-angiotensin-aldosterone system (RAAS). Given this, treatment with an ACE inhibitor alone, cannot explain the regression of LV hypertrophy (and RV hypertrophy) in this patient. However, surgical closure of the ASD remains to be undertaken at the time of writing this case report.

We acknowledge that ASD and hypertension could have contributed to this patient's cardiac manifestations; these causes alone cannot explain the significant improvement in her cardiac function after surgery for her adrenal tumor. Vice versa, acute aggravation of hypertensive heart failure combined with ASD but not aldosterone could develop similar condition. It seems hard to estimate potential role of aldosterone for heart failure using only from this single case. However, the demonstration of inward regression of both LV and RV hypertrophy, as well as the decrement of RA diameter (regarded as an indicator of cardiac geometry) in repeated echocardiography after adrenalectomy could provide an indirect proof of causal role in aldosterone excess.

Conclusions
===========

Patients with primary aldosteronism are known to be at risk of developing hypertensive heart disease and left ventricular hypertrophy. As this case report has shown, patients may present with heart failure due to aldosteronism-induced biventricular cardiac hypertrophy, either by direct aldosterone toxicity or hypokalemia. Both aldosteronism and hypokalemia can be normalized following adrenalectomy in a patient with adrenocortical adenoma.

In a patient with pre-existing ASD, this congenital defect may provide an initial stimulus to right ventricular and pulmonary vascular remodeling, and surgical closure of the ASD can await treatment of the cause of the primary aldosteronism. If an adrenocortical adenoma is identified on imaging, surgery should be planned as soon as possible. This case has demonstrated a mechanistic explanation for both the increased cardiovascular risk and improved prognosis for patients who undergo adrenalectomy for primary aldosteronism due to adrenal adenoma.
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![Chest radiographs before surgery. Posterior-anterior (PA) and lateral chest X-radiograph showing an enlarged cardiac silhouette, with left ventricle (LV), left atrium (LA), right ventricle (RV), and right atrium (RA) enlargement and a cardiothoracic ratio \> 55%.](amjcaserep-18-963-g001){#f1-amjcaserep-18-963}

![Transthoracal echocardiography measurements at initial admission in 2014. Left ventricle (LV) showed concentric hypertrophy (interventricular septal thickness 1.2 cm) in parasternal long-axis view (**A**), four chamber view (**B**), m-mode (**C**) and left-to-right flow across the secundum ASD in the apical four chamber view (**D**).](amjcaserep-18-963-g002){#f2-amjcaserep-18-963}

![Adrenal tumor visualization. Pre-operative view: (**A**) Axial and (**B**) coronal CT section of the abdomen showing a solitary tumor in the right adrenal topography (black arrows). (**C**) Intra-operative view and (**D**) Gross appearance of the specimen showing a 4×2.5 cm exophytic adrenal mass excised from right suprarenal area. The tumor is sharply circumscribed and is non-necrotic. The yellow color was thought to result from the abundant lipid content within the tumor.](amjcaserep-18-963-g003){#f3-amjcaserep-18-963}

![Adenocortical adenoma comprising of lipid-laden cells arranged in an alveolar pattern. Hematoxyline and eosin stain, (**A**) magnification ×40 and (**B**) ×100. (**C**) Tumor cells had clear cytoplasm, round and uniform nuclei, which favored adrenocortical adenoma (×400).](amjcaserep-18-963-g004){#f4-amjcaserep-18-963}

###### 

Laboratory data and blood gas analysis.

                                                  **Results**   **Normal value**          
  ----------------------------------------------- ------------- ------------------ ------ ---------------------------------------------------------------
  **Laboratory examination**                                                              
  Hemoglobin, gr/dL                               12.0          ND                 11.6   12--15
  Hematocrit, %                                   36.6          ND                 34.5   35--37
  Leukocyte, ×10^3^/mm^3^                         7.2           ND                 8.4    5.0--10.0
  Random blood glucose, mg/dL                     104           ND                 117    \<200
  Creatinine, mg/dL                               0.98          ND                 0.76   0.5--1.5
  Sodium, mMol/L                                  143           ND                 140    135--145
  Potassium, mMol/L                               2.2           ND                 4.1    3.5--5.5
  Calcium, mMol/L                                 2.1           ND                 2.3    2.1--2.5
  Magnesium, mMol/L                               0.87          ND                 0.85   0.74--0.99
  CPK, U/L                                        1,257         ND                 52     29--200
  CKMB, U/L                                       221           ND                 14     \<15
  Urinary sodium excretion, mMol/24 hours         167           ND                 ND     40--220
  Urinary potassium excretion, mMol/24 hours      43            ND                 ND     \<30
  **Blood gas analysis**                                                                  
  pH                                              7.57          ND                 7.35   7.35--7.45
  FiO~2~, %                                       32            ND                 21     
  PO~2~, mmHg                                     112           ND                 97     83--108
  PCO~2~, mmHg                                    33            ND                 33     35--45
  HCO~3~, mMol/L                                  34.1          ND                 18.2   18--23
  Base excess                                     +11.6         ND                 −2.4   ±2.5
  O~2~ saturation, %                              99            ND                 99     95--100
  **Endocrine evaluation**                                                                
  PAC, ng/mL (supine)                             56            47                 8.2    \<15[^a^](#tfn2-amjcaserep-18-963){ref-type="table-fn"}
  PRA, ng/mL/hour                                 0.13          0.09               0.27   0.5--3.3[^a^](#tfn2-amjcaserep-18-963){ref-type="table-fn"}
  PAC-to-PRA ratio, ng/dL per ng/mL/hour          430.7         522.2              30.4   \<30[^a^](#tfn2-amjcaserep-18-963){ref-type="table-fn"}
  24-hour urine free cortisol, nMol/day           13.8          ND                 ND     11.2--80.3[^b^](#tfn3-amjcaserep-18-963){ref-type="table-fn"}
  Cortisol level after 1 mg DST, µg/dL (8 A.M.)   17.6          ND                 ND     5--25[^b^](#tfn3-amjcaserep-18-963){ref-type="table-fn"}
  24-hour urine VMA, mg/day                       3.6           ND                 ND     \<11[^b^](#tfn3-amjcaserep-18-963){ref-type="table-fn"}

CPK -- creatine phosphokinase; CKMB -- creatine-kinase isoenzyme-myocardial band; PAC -- plasma aldosterone concentration; DST -- dexamethasone suppression test; PRA -- plasma renin activity; ND -- not determined; VMA -- vanilylmandelic acid. From reference:

Funder JW, et al. (J Clin Endocrinol Metab 2008);

Petersenn S, et al. (Ann NY Acad Sci 2006).

###### 

Serial measurements on echocardiography, before and after adrenalectomy.

  Parameter                  Before adrenalectomy   After adrenalectomy   Normal value   
  -------------------------- ---------------------- --------------------- -------------- ---------
  LAD, mm                    45                     45                    32             19--40
  LVDd, mm                   61                     62                    44             38--56
  LVDs, mm                   54                     58                    31             22--40
  LVM, g                     518.7                  473.6                 240            67--150
  LVMI, g/m^2^               357.7                  284.4                 142            \<105
  IVSd, mm                   14                     12                    12             6--9
  LVPWd, mm                  16                     16                    14             7--11
  Ejection fraction, %       23                     17                    56             50--85
  Fractional shortening, %   11                     8                     29             \>25
  E/A ratio                  0.5                    0.4                   0.8            \>1
  E Desc time                283                    277                   150            \<220
  RA major, mm               57                     58                    49             29--45
  RVDd, mm                   32                     34                    17             7--26
  RVD1, mm                   46                     ND                    30             20--28
  RVD2, mm                   44                     ND                    35             27--33
  RV EDWT, mm                8                      9                     6              ≤5
  RAP, mmHg                  5                      10                    5              0--5
  RVSP, mmHg                 48                     60                    42             30--35
  TAPSE, mm                  26                     27                    27             \>15

LAD -- left atrial diameter; LVDd -- left ventricular internal diameter end-diastole; LVDs -- left ventricular internal end systole; LVM -- left ventricular mass; LVMI -- left ventricular mass index; IVSd -- interventricular septal wall thickness at end-diastole; LVPWd -- left ventricular posterior wall thickness at end diastole; LV FS -- left ventricular fractional shortening; ND -- not determined; RA -- right atrial; RA major -- right atrial major dimension; RVDd -- right ventricular internal diameter at end-diastole; RVD1 -- basal right ventricular diameter; RVD2 -- mid right ventricular diameter; RV EDWT -- right ventricular end diastolic wall thickness; RAP -- right atrial pressure; RVSP -- right ventricular systolic pressure; TAPSE -- tricuspid annular plane systolic excursion.
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